	US 11,884,947 B2
	Fusion proteins for base editing
Jia Chen, Shanghai (CN); Li Yang, Shanghai (CN); Xingxu Huang, Shanghai (CN); Bei Yang, Shanghai (CN); Xiao Wang, Shanghai (CN); and Jianan Li, Shanghai (CN)
Assigned to ShanghaiTech University, Shanghai (CN)
Appl. No. 16/770,572
Filed by ShanghaiTech University, Pudong New Area (CN)
PCT Filed Feb. 22, 2019, PCT No. PCT/CN2019/075897 § 371(c)(1), (2) Date Jun. 5, 2020, PCT Pub. No. WO2019/161783, PCT Pub. Date Aug. 29, 2019.
Claims priority of application No. PCT/CN2018/076991 (WO), filed on Feb. 23, 2018; and application No. PCT/CN2018/100411 (WO), filed on Aug. 14, 2018.
Prior Publication US 2021/0163913 A1, Jun. 3, 2021
Int. Cl. C12N 9/78 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01); C12N 15/01 (2006.01)

CPC C12N 9/78 (2013.01) [C12N 9/22 (2013.01); C12N 15/01 (2013.01); C12N 15/907 (2013.01); C12Y 305/04 (2013.01); C07K 2319/00 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01)]

14 Claims

1. A fusion protein comprising a first fragment comprising an apolipoprotein B mRNA editing enzyme catalytic subunit 3A (APOBEC3A) and a second fragment comprising a clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas) protein, wherein the APOBEC3A is a mutant of human APOBEC3A having a mutation selected from the group consisting of D131Y, Y132D, W104A, P134Y and combinations thereof, according to residue numbering in SEQ ID NO:1, wherein the amino acid sequence of the fusion protein is at least 85% identity to SEQ ID NO: 1, and wherein the mutant retains cytidine deaminase activity.